Latest Administration News

Praemium Limited reports a 2.2% increase in funds under administration for Q4 FY25, driven by strong gains in Spectrum and SMA platforms, alongside operational upgrades including AI-driven initiatives. However, OneVue platform experiences a significant decline.

Praemium reports a 12% rise in total Australian funds under administration to $64.3 billion in Q4 FY2025, driven by strong inflows into its Spectrum platform and growth in Separately Managed Accounts. However, Powerwrap continues to face net outflows.

Insignia Financial reported a 2.6% rise in Funds Under Management and Administration to $330.3 billion, driven by record net inflows into its MLC Expand platform and a successful Master Trust transition to SS&C.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Horizon Gold Limited has announced a $7 million non-renounceable entitlement offer alongside a $5 million placement to fund its Gum Creek Gold Project and repay debt. The offer opens on 29 July and closes on 12 August 2025.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Barton Gold Holdings has revealed a preliminary A$26 million refurbishment plan for its Central Gawler Mill, aiming to restart production by the end of 2026 with significant cost and operational advantages.

Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.

Rincon Resources Limited has announced a non-renounceable entitlement offer to issue options aimed at raising approximately $97,520, fully underwritten by Golden Triangle Capital Pty Ltd. The offer may lead to a 25% dilution if all options are exercised.